NFA
IMDX

Nationwide Fund Advisors’s Insight Molecular Diagnostics IMDX Stock Holding History

Nationwide Fund Advisors’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-84
Closed -$8K – 3291
2016
Q1 		$8K Buy
+84
New +$7.44K ﹤0.01% 3170

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

Nationwide Fund Advisors's IMDX Position: Q2 2016 in Review

Nationwide Fund Advisors sold out of Insight Molecular Diagnostics (IMDX) in Q2 2016, closing a stake of 84 shares — an estimated $8K sold.

Nationwide Fund Advisors first reported a position in IMDX in Q1 2016 and held it in 1 quarter. The position peaked at $8K in Q1 2016. 34 funds tracked by Wall St. Rank hold IMDX as of Q2 2016.

  • Nationwide Fund Advisors reported no remaining Insight Molecular Diagnostics position as of Q2 2016 after selling out during the quarter.
  • Nationwide Fund Advisors sold 84 Insight Molecular Diagnostics shares in Q2 2016, an estimated $8K.
  • Nationwide Fund Advisors first reported a position in Insight Molecular Diagnostics in Q1 2016 and held it in 1 quarter.
  • Nationwide Fund Advisors's Insight Molecular Diagnostics position peaked at $8K in Q1 2016.
  • 34 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2016.

Based on Nationwide Fund Advisors's 13F filing for Q2 2016, filed 9 Aug 2016.